

PATENT CASE AL01019

1642  
#6  
3/13/02  
\$3W

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Shih *et al.*

Serial No.: 09/955,383 ✓

Filed: September 18, 2001 ✓

)  
) Examiner: Not assigned yet  
)  
) Group Art Unit: 1642  
)  
)  
) Atty. Docket No.: AL01019

RECEIVED  
FEB 20 2002  
TECH CENTER 1600/2900

For: SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS  
OR ANTAGONISTS ✓

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

It is requested that the following documents cited in the application, as listed below and in the accompanying form PTO-1449, be considered and made of record.

**Documents cited in the Application:**

4,767,778  
5,352,707  
5,869,479  
WO 93/01812  
WO 93/12093  
WO 95/14007  
WO 98/58646  
WO 96/29315  
EU 0448 765 B1  
EU 0 420 396 B1

**Publications:**

Howson, Bioorganic & Medicinal Chemistry Letters, Two Novel, Potent and Selective Histamine H3 Receptor Agonists, Vol. 2, pp. 77-78, 1992.

Stark, J. Med. Chem. , Novel Carbamates as Potent Histamine H3 Receptor Antagonists with High in Vitro and Oral In Vivo Activity, 39, pp. 1157-1163.

Sasse, Bioorganic & Medicinal Chemistry , (Partial) Agonist/Antagonist Properties of Novel Diarylalkyl, Vol 8 (2000) pp. 1139-1149.

Bagley, J. Med. Chem. 1991, New 1-(Heterocyclalkyl)-4-(Propionanilido)-4-Piperidinyl, 34, pp 827-941.

Huls, Bioorganic & Medicinal Chemistry Letters, Diphenylmethyl Ethers: Synthesis and Histamine, Vol. 6, No. 16, pp. 2013-2018, 1996.

Buschauer, J. Med. Chem. 1989, Synthesis and in Vitro Pharmacology of Arpromidine, 32, pp 1963-1970, 1989.

Schulze, Arch. Pharm. (Weinheim), Synthese und kombinierte H1/H2-antagonistische, Vol. 327, pp. 455-462, 1994. -

Schulze, European Journal of Pharmaceutical Sciences, Combined histamine H1/H2 receptor antagonists, Vol 6, pp. 177-186, 1998.

van der Goot, Eur J. Med. Chem. , Isothiourea analogues of histamine as potent agonists, Vol 27, pp. 511-517, 1992.

Walczyński, Il Farmaco, Non-imidazole histamine H3 ligands, Vo. 54, pp. 684-694, 1999.

Brown, Br. J. Pharmac. , Pharmacological studies with SK & F 93944, Vol. 87, pp. 569-578, 1986.

West, Molecular Pharmacology, Identification of Two H3-Histamine Receptor Subtypes, Vol. 38, pp. 610-613, 1990.

Clapham, Brit. J. Pharm. Suppl. , Ability of the Selective Histamine H3 Receptor Antagonist, Vol. 110, pp. Abs. 65P, 00/00, 1993.

Yokoyama, European Journal of Pharmacology, Effect of Thioperamide, Vol. 234, pp 129-133, 1993.

Schlicker, Br. J. Pharmacol., Novel Histamine H3 Receptor Antagonists, Vol. 112, pp. 1043-1048, 1994.

Leurs, Progre. Drug. Res. , The Histamine H3-Receptor, Vol. 39, pp. 127-165, 00/00, 1992.

Lipp, Histamine Receptor, Pharmacochimistry of H3-Receptors, pp. 57-72, 00/00, 1992.

Stark, European Journal of Pharmaceutical Sciences, New potent Histamine H3-Receptor Vol 3, pp. 95-104, 1995.

Lipp, Histamine Receptor, Pharmacochimistry of H3-Receptors, pp. 57-72, 00/00, 1992.


Stark, European Journal of Pharmaceutical Sciences, New potent Histamine H3 Receptor Vol 3, pp. 95-104, 1995.

The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case. Since no Office Action has issued on the merits of this case, Applicants believe that no fee is due at this time. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365.

If the Examiner has any questions, the Examiner is invited to contact the undersigned.

February 6, 2002  
Schering-Plough Corporation  
2000 Galloping Hill Road  
Patent Department, K-6-1,1990  
Kenilworth, NJ 07033  
Tel: (908) 298-5068  
Fax: (908) 298-5388

Respectfully submitted,





Palaiyur S. Kalyanaraman  
Attorney for Applicants  
Reg. No. 34,634

I hereby certify that this correspondence  
is being deposited with the U.S. Postal  
Service as First Class Mail in an envelope  
addressed to Assistant Commissioner for  
Patents, Washington, D.C. 20231 on

February 7, 2002

Palaiyur S. Kalyanaraman  
Registered Representative

 2/7/02  
Signature and Date of Signature



#6

Sheet 1 of 2

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: AL01019	SERIAL NO.: 09/955,383
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT: ASLANIAN	
		FILING DATE: Sept. 18, 2001	GROUP: 1642

### U.S. PATENT DOCUMENTS


*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA	4,767,778	8/88	U.S. PATENT			
AB	5,352,707	10/94	U.S. PATENT			
AC	5,869,479	2/99	U.S. PATENT			
AD						
AE						
AF						

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AG	WO 93/01812	2/93	INTERNATIONAL PATENT			
AH	WO 93/12093	6/93	INTERNATIONAL PATENT			
AI	WO 95/14007	5/95	INTERNATIONAL PATENT			
AJ	WO 98/58646	12/98	INTERNATIONAL PATENT			
AK	WO 96/29315	9/96	INTERNATIONAL PATENT			
AL	EU 0448 765 B1	3/90	EUROPEAN PATENT			
AM	EU 0 420 396 B1	7/90	EUROPEAN PATENT			
AN						
AO						

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	Howson, Bioorganic & Medicinal Chemistry Letters, Two Novel, Potent and Selective Histamine H3 Receptor Agonists, Vol. 2, pp. 77-78, 1992.
AQ	Stark, J. Med. Chem. , Novel Carbamates as Potent Histamine H3 Receptor Antagonists with High in Vitro and Oral In Vivo Activity, 39, pp. 1157-1163.
AR	Sasse, Bioorganic & Medicinal Chemistry , (Partial) Agonist/Antagonist Properties of Novel Diarylalkyl, Vol 8 (2000) pp. 1139-1149.
AS	Bagley, J. Med. Chem. 1991, New 1-(Heterocyclylalkyl)-4-(Propionanilido)-4-Piperidinyl, 34, pp 827-941.
AT	Huls, Bioorganic & Medicinal Chemistry Letters, Diphenylmethyl Ethers: Synthesis and Histamine, Vol. 6, No. 16, pp. 2013-2018, 1996.
AU	Buschauer, J. Med. Chem. 1989, Synthesis and in Vitro Pharmacology of Arpromidine, 32, pp 1963-1970, 1989.
	Schulze, Arch. Pharm. (Weinheim), Synthese und kombinierte H1/H2-antagonistische, Vol. 327, pp. 455-462, 1994. -
AV	Schulze, European Journal of Pharmaceutical Sciences, Combined histamine H1/H2 receptor antagonists, Vol 6, pp. 177-186, 1998.
AW	van der Goot, Eur J. Med. Chem. , Isothiourea analogues of histamine as potent agonists, Vol 27, pp. 511-517, 1992.
AX	Walczynski, Il Farmaco, Non-imidazole histamine H3 ligands, Vo. 54, pp. 684-694, 1999.
AY	Brown, Br. J. Pharmac. , Pharmacological studies with SK & F 93944, Vol. 87, pp. 569-578, 1986.
AZ	West, Molecular Pharmacology, Identificatin of Two H3-Histamine Receptor Subtypes, Vol. 38, pp. 610-613, 1990.
BA	Clapham, Brit. J. Pharm. Suppl. , Ability of the Selective Histamine H3 Receptor Antagonist, Vol. 110, pp. Abs. 65P, 00/00, 1993.
BB	Yokoyama, European Journal of Pharmacology, Effect of Thioperamide, Vol. 234, pp 129-133, 1993.
BC	Schlicker, Br. J. Pharmacol., Novel Histamine H3 Receptor Antagonists, Vol. 112, pp. 1043-1048, 1994.
BD	Leurs, Progre. Drug. Res. , The Histamine H3-Receptor, Vol. 39, pp. 127-165, 00/00, 1992.



BE	Lipp, Histamine Receptor, Pharmacochimistry of H3-Receptors, pp. 57-72, 00/00, 1992.
BF	Stark, European Journal of Pharmaceutical Sciences, New potent Histamine H3-Receptor Vol 3, pp. 95-104, 1993
BG	
EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
FEB 20 2002  
TECH CENTER 1600/2900